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I. Introduction 
1. Common variable immunodeficiency (CVID) 
1.1 Epidemiology 
Common variable immunodeficiency (CVID) is the most prevalent primary immune 
disorder. Its prevalence is estimated to be 1 in 25 000 to 50000 individuals, both 
sexes are equally affected (1).Compared to other primary immunodeficiencies which 
are diagnosed before age 2, mean age of onset is in late childhood or early 
adulthood (mean age 23 to 28 years (1)). Diagnosis is often delayed for several years 
due to the various clinical manifestations (1).  
1.2 Classification 
CVID is a heterogenous disorder, leading to frequent and severe infections as well as 
gastro-intestinal dysregulation, auto-immunitiy, lymphoproliferative and 
granulomatous disease that might degenerate to lymphoproliferative malignancies. 
Manifestations vary in frequency and severness from one patient to another. In the 
past few years several studies showed associations between B-cell defects and 
specific phenotypes (2)(3)(4)(5). According to these studies, splenomegaly, 
granulomatous disease and auto-immune cytopenia are associated to a reduction of 
total and / or switched memory B cells, and patients with an increase in CD21low B 
cells are more frequently subjected to splenomegaly and auto-immune disorders 
(2)(3)(4)(5). In 2008 the EUROclass trial improved the former Paris- and Freiburg-
classifications by developing a new organization, based upon B-cell abnormalities 
and clinical courses of CVID (2). The following divisions have been established: 
presence (B+) or absence (B-) of circulating B lymphocytes; the B+ group is sub-
divided according to the proportion of switched memory B cells (smB + or -). Further 
on the possible increase of two B-cell subsets is taken into account: transitional B-
cells and CD21low B cells (Figure 1).  
The french DEFI-study team performed further investigations including T-cell 
dysfunction. They first classified their patients using the EURO-class definition. Then 
they divided patients into four groups based upon the most common symptoms of 
CVID: infections only (IO), lymphoproliferation, autoimmune cytopenia and chronic 
enteropathy. They found the following associations: In the infections only group a 
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decrease in smB cells as well as the plasmablastic population could be shown. In the 
T-cell compartement a reduction of naive CD4 and CD8 cells associated to an 
increase in activated T-cells were the major difference compared to healthy controls. 
In the three remaining clinical groups the abnormalities were more pronounced than 
in the IO-group, but with a modification in the CD21low population, which was normal 
in the IO group (6). 
 
Figure 1: The EUROclass classification scheme (adapted from Wehr C et al. (2)) : 
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1.3 Diagnosis 
The diagnosis of CVID is based upon 1) the exclusion of other known 
immunodeficiency disorders, 2) the presence of hypogammaglobulinemia of at least 
two classes of immunoglobulins (Igs) (IgG and IgA or IgM), 3) impaired functional 
antibody responses to protein- or polysaccharide based vaccines (i.e. diphtheria, 
tetanus or S. pneumoniae respectively) (7).  
1.4 Symptoms 
Patients present a heterogenous set of symptoms. These symptoms encompass 
respiratory tract infections, gastro-intestinal diseases, auto-immune disorders, 
granulomateous disease and patients with CVID are at a higher risk for malignancies 
(1). 
Sino-pulmonary disease: The most frequent clinical presentation are upper and lower 
respiratory tract infections (sinusitis, otitis media, pneumonia, bronchitis), which may 
be acute, recurrent or chronic (8). They are mainly caused by Streptococcus 
pneumoniae, Klebsiella pneumoniae and Haemophilus influenzae (1). Most studies 
report a prevalence of 91% to 95% of upper and lower respiratory tracts infection 
(1)(9). Ten to 20% of CVID patients develop granulomatous-lymphocytic interstitial lung 
disease (GLILD). These non infectious, chronic lung diseases are associated with 
high morbidity, mortality and poor prognosis (7)(9). The granulomatous disease 
ressembles sarcoidosis and in addition to the lung, also lymph nodes, the liver, the 
skin, the spleen, the bone marrow, the gastrointestinal tract, the brain, the kidneys 
may be affected (1). 
Chest X-ray or CT show different abnormalities of the lung parenchyma: nodular 
infiltrates, pulmonary fibrosis, bronchectasis, all associated to either chronic or 
recurrent infections and lymphocitic infiltration (8)(7)(8). In the same cohort as 
mentioned above, at time of diagnosis more than 30% presented signs of chronic 
lung disease at CT-Scan, which increased up to 45% during follow-up (7).  
Gastro-intestinal disease: As in pulmonary disease, CVID patients present infectious 
as well as chronic gastro-intestinal abnormalities. The most common symptom is 
recurrent diarrhea. It is found in 10 to 50% of patients (1)(7)(9). In rare cases infectious 
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agents are identified: Gardia lamblia being the most common organism (7). These 
infections are more frequent in patients with an IgA deficiency than in those with a 
residual production of IgA (10). Among others, one of the known roles of IgA is the 
regulation of gut immunity by modulating the interaction between commensal flora 
and mucosal immunity (11). It has been observed that IgA deficiency is associated 
with increased infection frequency as well as with lymphocytic inflammatory changes, 
due to an excessive B-cell stimulation by expanded commensals (12). 
Gut biopsies present lymphoid hyperplasia, villous atrophy, granulomas, 
inflammatory bowel disease-like lesions, often associated with malabsorption, 
diarrhea and weight loss (7)(9)(10). The underlying causes of these histological changes 
have not been definitely identified, but seem to correlate with defects in cellular 
immunity (8). Gastric complications are discussed in the “neoplasia” section. 
Auto-immune disorders: Up to 25% of CVID patients suffer from auto-immune 
disorders (1)(7)(13)(14). Immune thrombocytopenic purpura (ITP) and auto-immune 
haemolytic anaemia (AIHA) are frequently encountered with a prevalence of 5-8% 
(1)(13). Cytopenias can manifest before the diagnosis of immunodeficiency (13)(15). They 
are strongly associated with splenomegaly, granulomatous disease and increased 
risk for hematological malignancy (14)(15)(16). 
Rheumatoid arthritis is present in 1-10% (15). Cases of other auto-immune disease 
can be found, such as neutropenia, Sjögren syndrom, thyroiditis, vitiligo, systemic 
lupus erythematosus, pernicious anemia (9)(13)(14). Autoantibodies (rheumatoid factor 
or antinuclear antibodies) are typically absent (15). 
The underlying mechanisms of auto-immune disorders in CVID have been analyzed 
in several studies (6)(14)(16)(17). Autoimmune cytopenia are associated with low 
numbers of class-switched memory B cells, low number of regulatory T cells and 
expanded CD21low B cells (2)(14).  
Neoplasia: It is hard to determine the incidence of cancer in CVID. Recent studies 
estimated an occurence in 15% of subjects with a 5-fold overall increased risk for 
cancer (7)(18). The group of patients suffering from lymphoid hyperplasia have an up to 
30-fold higher risk to develop non-Hodgkin lymphoma (7)(19). The incidence for this 
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malignancy is also related to female gender and a higher serum level of IgM (2)(7)(18). 
The combined Danish and Swedish study for cancer risk in CVID and their relatives, 
found no increased risk in close relatives, suggesting that the higher prevalence is 
more likely due to immunodeficiency than to inherited factors (19). 
Gastric cancer represents an important malignant manifestation of CVID with a 10-
fold increased risk of gastric cancer as compared to the general population 
(7)(10)(19)(20). In the general population H. pylori is listed as a class 1 carcinogen and is 
associated to a 2- to 9-fold increased risk to develop gastric lesions (20). One 
hypothesis could be that gastric cancer risk is increased among CVID patients due to 
a higher infection rate, which could not be confirmed up to now (20). The Swedish and 
Danish study however suggested a direct association of gastric cancer and 
immunodeficiency after comparing gastric cancer incidence of CVID patients and 
their relatives (19).  
1.5 Genetic 
Until now, only 15-20% of CVID cases have been associated to specific genetic 
defects (26). In particular, mutations in TNFRSF13B (TACI) (21), ICOS (22), CD19 (23), 
CD20 (24), CD81 (25), BAFF-R (26) , CD21 (27) genes were described. Of note, these 
studies were based on single gene target analyses; therefore, they do not exclude a 
possible role for other gene mutations. Several studies are assessing a potential 
genetic defect by whole genome analyses or full exome sequencing.  
1.6 Treatment  
Hypogammaglobulinemia is defined as plasmatic concentration of IgG lower than 4.9 
mg/mL, however, plasmatic IgG concentration of healthy individuals exceeds 7 
mg/mL (in 95% of cases). A plasmatic IgG level between 4.9 and 7 mg/mL does not 
completely rule out the diagnosis. Among those patients assessment of IgG 
subclasses may be of interest. The current gold-standard treatment is the 
transcomplementation of Ig administered intravenously every 3-4 weeks 
(intraveneous immunoglobulins (IVIg)). The goal of the treatment is 1) to prevent 
bacterial infections and 2) to reduce infection-associated morbidity and mortality (28). 
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The treatment of secondary affections depends on the manifestation. Breakthrough 
infections are usually treated with antibiotics, but surgical interventions can be 
necessary, mainly for sinuses (1)(29). Persistent hematologic auto-immune 
manifestations despite immunoglobulin substitution are usually treated by cortico-
steroids. Use of new biological drugs such as rituximab has been described in 
management of persistent or refractory cases of autoimmune cytopenia (7).  
Chronic lung diseases caused by repeated infections can be treated with prophylactic 
antibiotics, but severe cases may need oxygen therapy or even lung transplantation 
(7)(30). 
As there are several etiologies for enteropathy, the treatment varies with the cause. 
Anti-microbial agents are used for infections, whereas inflammatory bowel disease is 
treated the same way as in immunocompetent patients, with antibiotics or low dose 
steroids. In severe cases Infliximab has been used (7)(31). Gut biopsies often show 
villeous flattening suggesting coeliac sprue, but wheat withdrawel is rarely beneficial 
(7).  
Granulomatous disease can be treated with steroids or immuno-modulators, however 
it is still unclear to which patient, at which moment and whether the immuno-
suppressive effect of these drugs is deleterious or not (7)(17). 
Lymphomas respond to standard chemotherapy and rituximab protocols (7).  
Splenectomy is not recommended in patients suffering from CVID as severe 
infections might occur and patient’s deaths have been reported (7)(30). 
II. Aim of the study  
At the genetic and clinical level, CVID disorders are heterogenous, however Prof 
Pantaleo’s group hypothesized that they might share a common phenotype. When I 
started my master as a medical student, the team of Prof Pantaleo had already 
shown that CVID patients harbored reduced frequencies of bacteria-specific type 1 
CD4 T helper (Th1) cells (producing IFN-) and Th17 cells (producing IL-17A) 
(unpublished data). We therefore hypothesized that B-cell defect(s) in CVID patients 
might lead to CD4 T-cell impairment. Of note, CD4 T-cell functional impairment (i.e. 
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exhaustion) is commonly associated with the expression of co-inhibitory molecules 
during chronic viral infections (32)(33)(34)(35)(36). In this model, the progressive functional 
impairment of T cells is initiated by the loss of proliferative capacity, associated with a 
progressive reduction of IL-2 production capacity and, in the context of CD8 T cells, 
with a deficient killing capacity.  
In this context, the following points were evaluated: 1) the proliferation capacity of 
CD4 T cells of CVID patients in response to bacteria and viruses, 2) the co-inhibitory 
molecules (i.e. Programmed Death 1 (PD-1), 2B4, CD160, SLAM, CTLA-4, LAG-3, 
TIM-3) expression levels in both total and antigen-specific CD4 T cells and 3) the 
restoration of proliferation capacity by the blockade of PD-1/PD-1 ligands (PDL-1, 
PDL-2 interactions), 4) the levels of LPS (marker of bacterial translocation), together 
with IgG levels were also assessed in the plasma of CVID patients at various time 
points.  
During my master, I was involved in the collection of the clinical manifestations of our 
patients in order to characterize and compare our patients to current literature. I also 
participated in the fundamental research, particularly in the assessment of LPS levels 
and the expression of co-inhibitory molecules and CD4 T-cell proliferation. 
III. Material and methods 
Study groups. For this study, 31 CVID patients and 30 healthy individuals were 
recruited. Blood samples were obtained at the Centre Hospitalier Universitaire 
Vaudois (CHUV) and the Hôpital Henri Mondor, France or from the Blood Bank of 
Lausanne, Switzerland, for CVID patients and healthy individuals, respectively. The 
Institutional Review Board of the CHUV approved this study and informed consent 
was obtained from each individual. 
Cell isolation. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll 
gradient (GE healthcare). After centrifugation (300g; 20 min), PBMC ring was 
harvested in PBS-EDTA 2 mM (Laboratorium Dr Bichsel AG, and Ambion for PBS 
and EDTA, respectively). Cells were either used directly or cryopreserved in liquid 
nitrogen for future experiments. 
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Antibodies. The following antibodies were used: APC-H7-conjugated anti-CD3 
(clone SK7), FITC-conjugated anti-CD4 (clone RPA-T4), APC-conjugated anti-CD4 
(clone RPA-T4), PB-conjugated anti-CD4 (clone RPA-T4), APC-H7-conjugated anti-
CD8 (clone SK1), PerCP-Cy5.5-conjugated anti-CD8 (clone SK1), PerCP-conjugated 
anti-CD69 (clone L78), PECy7-conjugated anti-CD279 (PD-1; clone EH12.1), APC-
conjugated anti-TNF-α (MAbII), FITC-conjugated anti-CD25 (OX-39), PE-Cy-
conjugated anti-TNF-α (clone MabII) from BD biosciences (CA, USA); ECD-
conjugated anti-CD3 (clone UCHT1), ECD-conjugated anti-CD45RA (clone 2H4), 
ECD-conjugated anti-CD4 (clone T4) from Beckman Coulter (CA, USA); PECy5.5-
conjugated anti-2B4 (CD244; clone C1.7), PE-conjugated anti-SLAM (CD150; clone 
A12), PB-conjugated anti-CD57 (clone HCD57), AlexaFluor 647-conjugated anti-
CD160 (clone BY55) from Biolegend (CA, USA); EFluor 625NC-conjugated anti-CD8 
(clone RPA-T8), from eBioscience (CA, USA) and FITC-conjugated anti-CCR7 (clone 
150503), AlexaFluor 700-conjugated anti-HLA-DR (clone LN3) from R&D systems 
Inc. (MN, USA). 
Flow cytometry. Data were acquired on a LSR SORP four lasers (405, 488, 532 and 
633 nm) (Becton Dickinson), analyzed using FlowJo v9.4.11 (Treestar, Inc., Ashland, 
CR) and SPICE v5.21 (developed by Mario Roederer, National Institute of Health and 
downloaded from <http://exon.niaid.nih.gov/spice>) (37). At least 100,000 events were 
acquired for each sample. 
Assessment of CD4 T-cell proliferation. Mononuclear cells were re-suspended at 
106/ml in PBS and incubated for 7 min at 37°C with 0.25 M 5, 6-carboxyfluorescein 
succinimidyl ester (CFSE, Invitrogen) as previously described (38). The reaction was 
quenched with one volume of fetal calf serum (FBS; Institut de Biotechnologies 
Jacques Boy). Subsequently, cells were washed, cultured in 4% human AB serum 
(Institut de Biotechnologies Jacques Boy) RPMI (Gibco; Life Technologies). Cells 
were stimulated with Streptococcus pneumonia, Klebsellia pneumonia, 
Staphylococcus enterotoxin B (SEB, Sigma-Aldrich) (positive control) or unstimulated 
(negative control). After six days of in vitro T-cell expansion, dead cells were stained 
(4°C; 15 min) using the violet LIVE/DEAD stain kit (Invitrogen), and cells were 
  
 
 11 
stained  (4°C, 15 min) with anti-CD3-APC-H7, anti-CD4-ECD, anti-CD8-PerCP. 
Frequencies of proliferating CD4 T cells were assessed by flow cytometry.  
Assessment of CD4 T-cell exhaustion and differentiation. PBMCs were re-
suspended (106 cells/mL and per condition) in complete RPMI medium ((10% FCS, 
penicillin (100 u/ml) and streptomycin (100 µg/ml) (Bioconcept)). Dead cells were 
stained using the amcyan LIVE/DEAD stain kit (Life Technologies) (4°C, 15 min). 
Cells were stained (4°C, 15 min) with anti-CD3-APC H7, anti-CD4-PB, anti-CD8-
Efluor625NC, anti-2B4-PeCY5.5, anti-CD160-APC, anti-PD-1-PeCy7, anti-CD45RA-
ECD, anti-CCR7-FITC and anti-SLAM-PE. Data were acquired on an LSR SORP. 
Assessment of CD4 T-cell activation. PBMCs were re-suspended (106 cells/mL 
and per condition) in complete RPMI medium ((10% FCS, penicillin (100 u/ml) and 
streptomycin (100 µg/ml) (Bioconcept)). Dead cells were excluded using the amcyan 
LIVE/DEAD stain kit (4°C, 15 min). Cells were stained (4°C, 15 min) with anti-CD3-
ECD, anti-CD4-APC, anti-CD8-APC-H7, anti-CD69-PerCP, anti-CD25-FITC, anti-PD-
1-PeCy7, anti-HLADR-AlexaFluor 700 and anti-CD57-PB. Data were acquired on an 
LSR SORP. 
Restoration of CD4 T-cells proliferation. CFSE-labeled PBMCs (as previously 
described in methods) were stimulated with replication-deficient adenovirus serotype 
5 (Ad5) (1 µg/mL), bacteria pool (Staphylococcus aureus, Streptococcus 
pneumoniae, Pseudomonas aeruginosa, Salmonella typhi, Klebsellia pneumoniae 
and Escherichia coli, 5 x 107 CFU/ml), SEB as positive control or left unstimulated 
cells as negative control, in presence or in absence of PD-1 ligand 1 and 2 (PD-L1/2) 
(eBioscience). After 6 days of stimulation, cells were washed and stained with violet 
LIVE/DEAD stain kit (4°C, 15 min). Then cells were stained (4°C, 15 min) with anti-
CD3-APC-H7, anti-CD4-ECD, and anti-CD8-PerCP-Cy5.5. Data were acquired on an 
LSR SORP. 
mTNF-α production. Blood Mononuclear cells (106 cells/ml) were stimulated (18 
hours) with heat-inactivated bacteria pool (5 x 107 CFU/mL) or Ad5 (1 µg/mL) in 
complete RPMI containing TAPI-0 (10 µM; Calbiochem) and APC-conjugated anti-
TNF- (0.2 mg/mL) as described (39). Phytohaemagglutinin (PHA; Sigma) was used 
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as positive control and unstimulated cells as negative control.  At the end of the 
stimulation period, dead cells were stained using the violet LIVE/DEAD stain kit (4°C, 
15 min), cells were stained (4°C, 15 min) with anti-CD3-ECD, anti-CD4-FITC, anti-
CD8-APC-H7, and anti-PD-1 PeCY7. Data were acquired on LSR SORP and 
analyzed using FlowJo.  
LPS titration. Plasma were harvested during PBMC isolation or collected in the 
Immunology and Allergy diagnostic laboratory. Lipopolysaccharides (LPS) were 
quantified in plasma using limulus assay test (Charles River Laboratories). Briefly, 
plasma were diluted (1/50) in sterile water (Laboratorium Dr Bichsel AG) and 
samples were read in Endosafe assay (Charles River Laboratories). 
Immunoglobulin quantification. Total immunoglobulin G (IgG) quantification was 
performed in the Immunology and Allergy diagnostic laboratory by nephelemetry.  
Statistical analyses. Statistical significance (P values) was obtained using one-way 
ANOVA (Kruskal-Wallis test) followed by Student’s t test for multiple comparisons or 
a Spearman rank test for correlations. 
Analysis of patients medical history. Thirteen patients are followed at the Centre 
Hospitalier Universitaire Vaudois (CHUV), their medical history was analized, based 
upon the medical doctor’s documentation. Specific characteristics i.e. age, sex, Ig 
levels, therapy, pre-and postdiagnostic symptoms, family history were analized and 
documented in table 1. One patient was excluded, as she had normal levels of total 
IgG and IgA (13) a vaccinal response, probably further classified as sub-class 
deficiency, so only 12 patients could be definitely included. The 19 remainaing 
patients were included in the fundamental research, but their history could not be 
analyzed as they are followed at the unit of clinical immunology at the Hôpital Henri 
Mondor, in France. Considering the small number of patients, the results in „Clinical 
findings“ are only given in numbers and not in percentages. 
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IV. Results 
1. Clinical findings (see table 1 “clinical data”) 
1.1 Immunoglobulin Levels 
Eight out of 12 patients had total IgG levels under 2 mg/ml by the time of diagnosis, 
the other 4 had between 3 and 4 mg/ml. IgG subclasses could not be analyzed as 
they were not tested in all patients. All of them had a deficiency in IgA. IgM levels 
were too low in 5 out of 12 patients, the remaining 7 subjects were all clearly below 
0.7 g/l.  
 
1.2 CD4, CD8 and B-cell count 
Two patients could not be taken into account, as only the relative number of cells 
was known. Only 2 patients had a normal count of all subtypes. Total lymphocyte T-
count was normal in 5 patients, 3 only had a dicrease of total CD3 whereas the CD4, 
CD8 and CD19 count was normal. One patient presented a severe lymphopenia, 
unfortunately only his CD4 and CD8 T-cell counts were available. One patient had an 
increased number of CD8 T cells, another one in CD19 B cells. Finally only 2 patients 
lacked CD4 T cells and only 1 lacked CD8 T cells. 
 
1.3 Vaccine response 
The vaccinal response of CVID patients is low for protein- or polysaccharide based 
vaccines (i.e. diphtheria, tetanus or S. pneumoniae respectively) Antibody levels 
were determined in 7 out of 12 patients. Quantities were measured either directely at 
diagnosis, or one month post-vaccination. Four out of 7 patients had no, or a too low 
to be protective response. The 3 remaining responded with low levels of antibodies to 
one out of the three vaccinces tested.  
Of note, the assay performed at the division of Immunology and Allergy only detects 
specific antibodies. Therefore it is not possible to assess affinity maturation of 
vaccinal responses (40)(41). 
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1.4 Pre-diagnostic elements 
Patients documentations were analyzed for symptoms prior to the diagnosis of CVID. 
Most patients had suffered from their infections several years before the diagnosis of 
CVID was confirmed and the adequate treatment instored. 
All patients suffered from sinusitis, some patients needed antibiotic treatment several 
times per year. Severe sinusitis leading to meatectomies were found in 2 patients 
histories. Lower respiratory tract infections were present in 6 out of 12 patients, it was 
not always clear whether these were pneumonias or bronchitis. Gastro-intestinal 
problems were relevated in 2 patients. These patients suffered from diffuse 
abdominal pain, accompanied by diarrhea. An intestinal parasite was found in 1 
patient. Two patients had suffered from idiopathic thrombotic purpura in the past, one 
presented a vitiligo. 
 
1.5 Post-diagnostic elements 
After the diagnosis of CVID and the initiation of appropriate treatment, all patients still 
suffered from manifestations of CVID, but to a lower degree. 
Sino-pulmonary infections are highly represented, only 4 patients were symptom 
free. The others were less frequently infected, but infections could still be severe, 
needing surgical interventions (amygdalectomie, meatectomie).  
Pulmonary infections were reported in 2 patients, one of them with an Aspergilloma 
and an infection by Pneumocystis jirovecii. Interstitial lymphoid pneumopathies with 
obstructive symptoms were found in 2 patients. Gastro-intestinal manifestations, 
such as cramps, diarrhea or parasite infections (mainly Gardia lamblia) were found in 
4 patient treated by IVIgs. One of the patients had 3 episodes of spontanous 
bacterial peritonitis. Diffuse adenopathies or lymphoid hyperplasia lesions were found 
in 7 patients. They were located either in the mediastinal compartment, directely on 
the pulmonary hilum or in the abdominal cavity. One patient presented diffuse 
polyclonal lymphoid proliferation in the white brain matter, the lungs, the spleen and 
the liver. Two patients showed adenopathies in the axillary region and both of them 
suffered from granulomateous interstitial pneumopathies. One patient presented 
granulomateous uveitis. Hematological auto-immune manifestations were found in 3 
patients: one showed an episode of hemolytic anemia, the others thrombocytopenia. 
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At least 4 patients presented a documented splenomegaly which was operated or 
not. One patient had a splenectomie after an accident.  
 
2. Impaired bacteria-specific CD4 T-cell proliferative capacity of 
CVID patients 
We previously observed that CVID patients harbored reduced frequencies of IL-2- 
and IFN--producing bacteria-specific CD4 T cells. In order to assess bacteria-
specific CD4 T cells proliferation, blood mononuclear cells were labeled with CFSE 
and stimulated with heat-killed bacteria (either Gram positive (Staphylococcus 
aureus, Streptococcus pneumoniae) or Gram negative bacteria (Escherichia coli, 
Pseudomonas aeruginosa, Salmonella typhi and Klebsellia pneumoniae)) and 
proliferation was measured on CD3-positive T cells at day 6 by flow cytometry (Fig. 
2A). Proliferative responses were measured in 30 healthy individuals and 31 CVID 
patients. We showed that the proliferation capacity of bacteria-specific CD4 T cells in 
CVID patients was significantly (P<0.0015) reduced as compared to healthy 
individuals (Fig. 2A and B).  
3. CD4 T cells of CVID Patients express high levels of PD-1 
Considering that CD4 T cells of CVID patients harbored reduced capacity to produce 
cytokines and to proliferate (Fig. 2A and B), we postulated that CD4 T cells could be 
exhausted. To address this issue, the expression of co-inhibitory molecules was 
assessed by flow cytometry. For that purpose, PBMC of CVID patients (N=21) and 
healthy individual (N=30) were stained with monoclonal antibodies directed to PD-1, 
2B4, CD160, SLAM, CTLA-4, LAG-3, and TIM-3 and the expression of these 
molecules was evaluated by flow cytometry (Fig. 3A). We observed that CD4 T cells 
in CVID patients expressed significantly higher levels of PD-1 than in healthy 
subjects (P<0.0001) (Fig. 3B), suggesting the presence of functional exhaustion. 
However, we did not detect any other difference in co-inhibitory molecules 
expression (Fig. 3B). It has been observed that PD-1 expression is prevalent in T 
cells in effector memory stage of differentiation and is upregulated upon T-cell 
activation (42). Thus, the proportion of CD4 T cells at the various stages of 
differentiation (naïve, central memory, effector memory and terminally effector 
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memory) as well as the frequencies of CD4 T cells expressing other activation 
markers (CD69, CD25 and HLA-DR) were assessed by flow cytometry. No 
differences were observed in CD4 T-cell differentiation or activation (CD69, CD25 
and HLA-DR expression levels) between CVID patients and healthy individuals 
(Figure 4). Therefore, the possibility that the observed increase in PD-1 was 
associated to skewing of CD4 T-cell differentiation toward an effector memory 
phenotype or to activation of CD4 T cells was excluded.  
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Figure 2. Impaired bacteria-specific CD4 T-cell proliferative capacity of CVID 
patients. Blood mononuclear cells were labelled with CFSE and stimulated with 
heat-killed bacteria and proliferation was measured on CD3 positive T-cells at day 6. 
Proliferative responses were measured in 31 healthy individuals and 30 CVID 
patients. (A) Flow cytometry profiles of CD3 T-cells stimulated with S. pneumoniae 
and K pneumoniae. Representative examples of healthy individuals (#851) and CVID 
patients (#1) are shown. Unstimulated cell cultures (negative control) and cell 
cultures stimulated with SEB (positive control) are also shown. (B) cumulative data 
representing the percentage of bacteria-specific CD4 T-cell proliferation. P values 
were derived using Student’s t-test.  
Figure 3. CD4 T cells of CVID Patients express high levels of PD-1. Expression of 
PD-1, SLAM, CD160, 2B4, CTLA-4, LAG-3 and TIM-3 were evaluated in healthy 
individuals (N=30) and CVID patients (N=21) by flow cytometry. (A) Representative 
example of the expression of PD-1 and SLAM or CD160 and 2B4 in a representative 
healthy individual (#MP) and in a CVID patient (#3). (B) Cumulative data of co-
inhibitory molecules expression. P values were derived using Student’s t-test.  
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Figure 4. Differentiation and activation profiles of CD4 T cells of CVID patients. 
A) Proportion of naïve, central memory (CM), effector memory (EM) and terminally 
differentiated effector memory (TDEM) in CD4 T cells from CVID patients. B) 
Proportion of CD4 T cells expressing CD69, CD25, HLA-DR and PD-1 in healthy 
individuals and CVID patients. P values were derived from One-way ANOVA 
(Kruskal-Wallis test) followed by a Student’s t-test.  
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4. Bacteria-specific CD4 T cells of CVID Patients express high levels 
of PD-1 
We showed that PD-1 was increased on total CD4 T cells (P<0.0001) similarly to 
what was observed in the context of chronic infections such as HIV-1 (33)(35). In this 
model, HIV-1-specific but not CMV-specific CD8 T cells of viremic HIV patients 
expressed high levels of PD-1, suggesting that chronic antigen stimulation triggers 
the up-regulation of PD-1 and consequently functional impairment of HIV-specific 
CD8 T cells (33)(35). Interestingly, CVID patients suffer from recurrent bacterial 
infections (1)(43)(44), while no increase of acute viral infections (i.e. influenza) nor 
reactivation of chronic viral infections (i.e. EBV or CMV) was reported (45). Of note, we 
previously showed that bacteria-specific but not virus-specific CD4 T cells of CVID 
patients harbored reduced capacity to produce cytokines and to proliferate (data not 
shown). Therefore, we assessed whether PD-1 upregulation was restricted to 
bacteria-specific CD4 T cells. In the context of chronic viral infection, most of the 
study relies on the use of tetramer staining to identify virus-specific CD8 T cells and 
therefore evaluate their phenotype directly ex-vivo (33)(34)(35). However, in the context 
of bacteria-specific CD4 T-cell responses, MHC-II tetramer are poorly available and 
technical issues are still unresolved; in addition, virus-specific T-cell responses are 
usually oligoclonal while bacteria-specific T cell responses are more polyclonal 
(46)(47)(48)(49)(50). Thus, we took advantage of a recently described technique by haney 
et al., in Journal of Immunological Methods that exploits an inhibitor (TAPI-0) of TNF-
 converting enzyme (TACE) that blocks TNF-α release from the membrane, to 
identify specific CD4 T cells (39).  
Using this technique, the expression of PD-1 on bacteria-, virus- and tetanus toxoïd-
specific CD4 T cells were evaluated by flow cytometry (Fig. 5A and B). For that 
purpose, PBMCs of CVID patients (N=7) and healthy individuals (N=9) were 
stimulated for 18h with a pool of bacteria, or adenovirus (Ad5), or tetanus toxoid or 
PHA (positive control) in the presence of TAPI-0 and anti-TNF-α-APC monoclonal 
antibody (MAb). Unstimulated cells were used as negative control. Then, PBMCs 
were stained with monoclonal antibodies directed to PD-1, CD3, CD4 and CD8 and 
the expression of these molecules as well as of TNF-α was evaluated by flow 
cytometry (Fig. 5A). We observed that bacteria-specific but not Ad5/tetanus toxoid-
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specific CD4 T cells expressed significantly higher levels of PD-1 in CVID patients 
compared to healthy individuals (P<0.0001) (Fig. 6B).  
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Figure 5. Bacteria-specific CD4 T cells of CVID patients express high levels of 
PD-1. Expression of PD-1 by CD4 T cells were evaluated in healthy individuals (N=9) 
and CVID patients (N=7) by flow cytometry. Blood mononuclear cells were stimulated 
during 18h with heat-killed bacteria, Ad5, Tetanus Toxoid or PHA in the presence of 
TAPI-0 and anti-TNF-α-APC. (A) Representative flow cytometry profiles of bacteria-
specific CD4 T-cells of one healthy individual (#1093) and in a CVID patient (#7) are 
shown. (B) Proportion of antigen-specific CD4 T cells expressing PD-1. P values were 
derived using Student’s t-test.  
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5. PD-1 blockage restores bacteria-specific CD4 T-cell proliferation 
of CVID patients 
Programmed Death 1 (PD-1) is a T-cell regulator. Upon CD4 T-cell activation, the 
PD-1 expression is increased in order to negatively regulate immune response when 
the pathogen is cleared. PD-1 has two ligands, PD-L1 and PD-L2, which differ in 
localization: PD-L1 is expressed on hematopoietic and non hematopoietic cells, while 
PD-L2 expression is limited to DCs, macrophages and actif B cells (51). As described 
above, PD-1 expression can be related to T-cell activation, T-cell differentiation and 
T-cell exhaustion (42). We first showed that PD-1 over expression on CD4 T cells of 
CVID patients was not related to both T-cell activation and T-cell differentiation 
(Figure 4). Thus, we investigated the role of PD-1 in T-cell exhaustion. To assess the 
involvement of PD-1/PD-L1/2 axis in the impairment of bacteria-specific CD4 T-cell 
proliferation in CVID patients, mononuclear cells from CVID patients (N=6) were 
labeled with CFSE and stimulated or not with heat-killed bacteria, virus-derived 
antigens (internal control) or SEB (positive control) in presence or in absence of PD-
L1/2. The proliferation levels were measured on CD3+CD4+ T cells at day 6. 
Representative flow cytometry profiles (Fig. 6A) and cumulative data (Fig. 6B), 
showed that bacteria-specific but not virus-specific CD4 T-cell proliferation is restored 
by the blockade of PD-1/PD-L1/2 axis (P=0.026) (Fig. 6A and B). 
 
 
  
 
 22 
 
0 102 103 104 105
0
102
103
104
105
1.4
0 102 103 104 105
0
102
103
104
105
7.58
0 102 103 104 105
0
102
103
104
105
5.35
0 102 103 104 105
0
102
103
104
105
67.1
0 102 103 104 105
0
102
103
104
105
1.23
0 102 103 104 105
0
102
103
104
105
16.8
0 102 103 104 105
0
102
103
104
105
6.35
0 102 103 104 105
0
102
103
104
105
63.3
untreated
PDL-1/2
treatment
Gated on CD4+ cellsCVID #121
C
D
4
CFSE
Unstimulated Bacteria pool SEBAd5
Untreated Anti-PDL-1/PDL-2
treatment
P
e
rc
e
n
ta
g
e
 o
f 
p
ro
li
fe
ra
ti
n
g
 
(C
F
S
E
 lo
w
) 
b
a
c
te
ri
a
-s
p
e
c
if
ic
 C
D
4
 T
 c
e
ll
s
P=0.026
0
5
10
15
20
A B
Figure 6. PD-1 blockage restore CD4 T-cell proliferation of CVID Patients. Blood 
mononuclear cells were labelled with CFSE and stimulated with heat-killed bacteria or 
SEB in presence or in absence of anti-PD-L1/2 MAbs and proliferation was measured 
on CD4 positive T cells at day 6. Proliferative responses were measured in 6 CVID 
patients. (A) Flow cytometry profiles of bacteria-specific CD4 T-cells proliferation of 
one representative CVID patient (#4) are shown. Unstimulated cell cultures (negative 
control) and cell cultures stimulated with SEB (positive control) are also shown. (B) 
Percentage of bacteria-specific CD4 T-cell proliferation in presence or in absence of 
anti-PD-L1/2 MAbs. P values were derived using Student’s t-test.  
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6. Endotoxin levels in CVID patients correlate with IgG levels 
We postulated that bacteria-specific CD4 T-cell exhaustion might be due to bacteria 
antigens persistency. To address this hypothesis, the presence of endotoxins in 
plasma of CVID patients and healthy individuals was evaluated by an enzymatic 
reaction based on the amebocyte limulus assay. Briefly, the presence of endotoxins 
in the plasma cleaves a pro-enzyme (inactive) in an enzyme (active) that converts a 
chromogenic substrate in para-nitro-aniline detected at 405 nm. The proportion of 
individuals with endotoxemia and the levels of endotoxin were assessed in CVID 
patients transcomplemented or not with intravenous IgG (IVIG), subdivided in 3 
groups i.e. IgG titers < 4.9 mg/mL, between 4.9 and 7 mg/mL and > 7 mg/mL. The 
proportion of CVID patients harboring detectable levels of entotoxins reached 100%, 
50% and 22% for CVID patients with IgG < 4.9 mg/mL, between 4.9 and 7 mg/mL 
and > 7 mg/mL, respectively. Of note, none of the healthy individuals tested were 
positive for endotoxin (Fig. 6A). In addition, endotoxin levels in plasma were also 
dependent on IgG titers (Fig. 6B). Of note, both the proportion and the level of 
entotoxins were significantly higher in untreated CVID patients than in treated (IgG 
>7 mg/mL) CVID patients (P=0.0008 and P<0.0001, respectively). Furthermore, the 
endotoxemia inversely correlated with the concentration of IgG (R=-0.5769, 
P<0.0001) (Fig. 7C). Finally, we monitored the presence of endotoxin in CVID 
patients (N=5) before and after IVIG treatment (IgG titers were increasing from <4.9 
to >4.9) (Fig. 7D). In all cases, endotoxin levels significantly decreased upon initiation 
of treatment indicating that immunoglobulin transcomplementation reduces bacterial 
translocation in CVID patients (P=0.005) (Fig. 7D).  
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Figure 7. Endotoxin levels in CVID patients correlate with IgG levels.  (A) 
Proportion of individuals with endotoxemia. (B) Levels of endotoxin in plasma of 
healthy individuals and CVID patients. (C) Endotoxin levels correlate with IgG 
levels. (D) Immunoglobulin transcomplementation reduces endotoxin levels in 
CVID patients. P values were derived from either Chi-square analysis for 
comparison of positive proportions, or One-way ANOVA (Kruskal-Wallis test) 
followed by a Student’s t-test in the context of multiple comparisons.  
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V. Discussion 
In this study we looked at a complex disease from different angles. We examined our 
cohorts clinical status and at the same time tried to get a better understanding of 
underlying molecular mechansims.  
Clinically CVID is a heterogenous disease. Symptoms and manifestations vary 
between individuals and correlations can be established only with great difficulty. 
One of our aims was to analyze patient’s medical histories to compare our findings to 
current literature. We realised that even in a cohort as small as 12 patients, all known 
clinical manifestations of the disease, except for lymphoid malignancies, were 
present. We could confirm that following IVIg treatment, CVID manifestations are 
usually less frequent, but complications such as auto-immunity, inflammatory disease 
or gastro-intestinal symptoms may remain (29)(52)(53). 
 
From a phenotypical point of view all patients harbor an Ig deficiency. At the genetic 
level in only 15-20% of patients an association with a mono-genetic defect in genes 
involved in B-cell costimulation or B-cell receptor (BCR) signaling i.e. TACI, ICOS, 
CD19, CD20 or CD81 (17)(22)(23)(24)(25) could be identified. For the remaining 80% 
several mechanisms have been proposed, but no common underlying cause was 
found so far.  
 
We were able to show other homogenous aspects of CVID. We demonstrated that 
bacteria-specific but not virus-specific CD4 T cells in CVID patients harbored reduced 
capacities to produce cytokines (IL-2, IL-17A and IFN-) and to proliferate. This loss 
of CD4 T-cell function might be the consequence of 1) T-cell differentiation to the 
terminal stage (senescence) or 2) exhaustion of antigen-specific CD4 T cells. Both 
mechanisms can be caused by a chronic bacteria-derived antigen load, which could 
be present due to the defect of Ig production or another mechanism, in CVID 
patients.  
We could eliminate 1) T-cell senescence by investigating the level of differentiation 
(using CCR7 and CD45RA markers) and senescence (using CD57 marker (34)) of 
CD4 T cells in CVID patients compared to healthy individuals. No differences were 
observed in 1) the proportion of CD4 T cells in the three populations of antigen-
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experienced CD4 T cells i.e. central memory, effector memory and terminally 
differentiated effector memory CD4 T cells, and 2) the proportion of CD4 T cells 
expressing CD57 (data not shown).  
We then assessed the expression of co-inhibitory molecules, classically involved in 
T-cell exhaustion. This process takes place in order to avoid excessive inflammatory 
response and the consequent tissue damage. T-cell exhaustion leads to a 
progressive loss of T-cell functions, such as cytokine production. So far, this 
mechanism has been observed in chronic viral infections (54). Therefore, we assessed 
the expression of co-inhibitory receptors associated to T-cell exhaustion i.e. PD-1, 
2B4, CD160, SLAM, CTLA-4, LAG-3, and TIM-3 and showed that only PD-1 was up-
regulated on total CD4 T cells of CVID patients. To determine whether the increase 
of PD-1 was a general feature of CD4 T cells in CVID patients or if it was linked to 
specific antigen stimulation, we compared PD-1 expression levels on virus-specific 
CD4 T cells versus bacteria-specific CD4 T cells. We demonstrated that PD-1 was 
increased preferentially in bacteria-specific CD4 T cells, consistently to the functional 
defects previously described. These evidences suggest that the increased 
expression of PD-1 might be induced by chronic exposure to bacterial antigens, 
leading to functional impairment of bacteria-specific CD4 T cells. The involvement of 
PD-1 in the impairment of CD4 T cells was further assessed by proliferation assay in 
presence or in absence of blocking agents of the PD-1/PD-1 ligands pathway. This 
test demonstrated the involvement of PD-1/PD-1 ligands in the impairment of 
bacteria-specific CD4 T cells.  
Our next step was to determine whether an antigen load was present or not. In the 
context of chronic viral infections, PD-1 expression levels directly correlate with viral 
loads (33)(35). We therefore postulated that the levels of PD-1 expression in CVID 
patients could be correlated to endotoxemia (marker of bacterial translocation). As 
patients with CVID are unable to protect themselves against extra-cellular bacteria 
and therefore suffer from chronic bacterial infections, it is possible that bacterial 
antigens persist, which leads to T-cell exhaustion. In order to confirm our hypothesis, 
we measured the presence of endotoxins in CVID patients plasma and we showed 
that 1) the levels of endotoxin inversely correlated with IgG concentration, 2) IVIg 
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treated CVID patients harbored reduced endotoxemia and 3) IgG concentration 
exceeding 7 mg/mL strongly reduced both, the proportion of CVID patients with 
detectable endotoxemia and the concentration of endotoxins in plasma. We showed 
that transcomplementation with immunoglobulins allows the reduction of bacterial 
translocation in CVID patients. To further confirm our hypothesis, we are currently 
longitudinally evaluating PD-1 expression level (on total and bacteria-specific CD4 T 
cells), in parallel with endotoxemia in plasma of CVID patients treated by IVIG. 
Preliminary results suggest that in addition to a strong reduction of the endotoxin 
levels in plasma, PD-1 levels on CD4 T cells decrease over-time under therapy. 
Taken together, our observations suggest that primary B-cell defect(s) in CVID 
patients leads to recurrent bacterial infections. These are associated to an acquired 
(secondary) impairment of CD4 T cells, which may in turn exacerbate the lack of 
protection against extracellular bacteria. 
All patients share the same basic treatment, which should prevent severe infections 
and decrease general inflammation leading to a lower morbidity and mortality rate 
(7)(52)(53). The standard dose of IVIg is 400-600 mg/kg body weight per month (7). At 
diagnosis, some patients present initial IgG levels of 1 mg/ml, where as others still 
produce 3-4mg/ml. Unfortunately it is impossible to determine whether these 
antibodies are functional or not. For this reason as well as for the findings explained 
above, we would suggest an IgG target level of “initial level +6 mg/ml”, instead of a 
standard target level of 7mg/ml (valid at the University hospital of Lausanne, 
Switzerland).  
As for the diagnostic approach, different things should be taken into account: when a 
new diagnosis is made, global Ig levels should be measured, B-and T-cell 
quantitation should be assessed by flow-cytometry and B-cell subsets should be 
determined (1). This would allow to classify patients and to determine their clinical 
phenotype associated to B- and T-cell specificities. In this case, possible risk factors 
for later complications would be known from the beginning of treatment. Also, genetic 
testing for known gene defects could be contributive.  
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LPS detection in CVID patients is not useful to detect infectious or inflammatory 
processes. Erythrocyte sedimentation rate and C-reactive-protein are sensitive 
markers for this purpose. However, these laboratory tests are not specific to indicate 
bacterial translocation. Therefore, LPS detection can be of value to confirm bacterial 
translocation to observe specific cellular mechanisms encountered in this condition.  
Although up to now it is not possible, it would be of interest to determine whether 
residual IgG and IgA produced by a patient are functional or not. This would allow to 
administrate more precise doses of IVIG therapy.  
VI. Perspectives 
We would like to perform genome wide comparisons between CVID patients, to 
eventually find other genetic defects. Our hypothesis is that multiple genetic defects 
lead to similar phenotypes. 
We would like to develop a cytofluometric panel to assess B-cell phenotypes as a 
standard at the University hospital in Lausanne. This panel would allow to further 
characterize CVID and other disorders, as described in the EUROclass trial (2). One 
further investigation could target the detection of IgG and IgA in the oro-pharyngeal 
mucosa in CVID patients versus healthy individuals. Indeed, IgG diffusion through 
mucosae might depend on the amount of plasmatic IgG. As patients have different 
levels of IgG, this could allow to determine the minimal IgG level needed to diffuse. 
Also, plasmatic IgA does not necessarily represent the amount of IgA dimers 
secreted in the mucosae. Taken together, these additional tests could help to further 
characterize CVID and contribute to explain different clinical phenotypes. 
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VII. Table 1 clinical data 
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Abstract 
Common variable immunodeficiency (CVID), is a disease that is characterized by 
hypogammaglobulinemia as well as a defect in T, B and dendritic cells. This leads to 
recurrent bacterial infection mainly caused by Streptococcus pneumoniae, Klebsiella 
pneumoniae and Haemophilus influenzae, as well as inflammatory manifestations, 
i.e. granulomateous disease, gastro-intestinal disorders and chronic lung disease. 
Intravenous Immunoglobulin (IVIg) therapy reduces CVID susceptibility to bacterial 
infections to some extend. We analyzed clinical aspects of patients from our 
database.  
We recently showed that bacteria-specific CD4 T cells of CVID patients were 
impaired. We therefor postulated that CVID patients may harbor an acquired T-cell 
deficiency also called exhaustion. 
To test this hypothesis, we performed a comprehensive investigation of the functional 
profiles of bacteria-specific CD4 T cells isolated from 31 healthy individuals and 30 
CVID patients.  
In the present study, we demonstrated that bacteria-specific but not virus-specific 
CD4 T cells in CVID patients harbored reduced proliferation capacity and expressed 
high level of PD-1. Interestingly, the blockade of PD-1/PD-1 ligands interactions 
restored partially bacteria but not virus-specific CD4 T-cell proliferation. Finally, we 
showed that 1) the level of endotoxins inversely correlates with IgG concentration, 2) 
IVIG treated CVID patients harbored reduced endotoxemia and 3) IgG concentration 
exceeding 7 mg/mL strongly reduces both the proportion of CVID patients with 
detectable endotoxemia and the concentration of endotoxins in plasma.  
Taken together our observations, suggest that primary B-cell defect(s) in CVID 
patients leads to recurrent bacterial infections that are associated to an acquired 
(secondary) impairment of CD4 T cells which may in turn exacerbate the lack of 
protection against extracellular bacteria. 
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